These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 31225609)

  • 1. Concentration-response model of rilpivirine in a cohort of HIV-1-infected naive and pre-treated patients.
    Néant N; Solas C; Bouazza N; Lê MP; Yazdanpanah Y; Dhiver C; Bregigeon S; Mokhtari S; Peytavin G; Tamalet C; Descamps D; Lacarelle B; Gattacceca F
    J Antimicrob Chemother; 2019 Jul; 74(7):1992-2002. PubMed ID: 31225609
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population pharmacokinetics of Rilpivirine in HIV-1-infected patients treated with the single-tablet regimen rilpivirine/tenofovir/emtricitabine.
    Néant N; Gattacceca F; Lê MP; Yazdanpanah Y; Dhiver C; Bregigeon S; Mokhtari S; Peytavin G; Tamalet C; Descamps D; Lacarelle B; Solas C
    Eur J Clin Pharmacol; 2018 Apr; 74(4):473-481. PubMed ID: 29374296
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Usefulness of therapeutic drug monitoring of rilpivirine and its relationship with virologic response and resistance in a cohort of naive and pretreated HIV-infected patients.
    Néant N; Lê MP; Bouazza N; Gattacceca F; Yazdanpanah Y; Dhiver C; Bregigeon S; Mokhtari S; Peytavin G; Tamalet C; Descamps D; Lacarelle B; Solas C
    Br J Clin Pharmacol; 2020 Dec; 86(12):2404-2413. PubMed ID: 32374049
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emtricitabine/rilpivirine/tenofovir disoproxil fumarate for the treatment of HIV-1 infection in adults.
    Kabbara WK; Ramadan WH
    J Infect Public Health; 2015; 8(5):409-17. PubMed ID: 26001757
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Population Pharmacokinetics and Pharmacogenetics Analysis of Rilpivirine in HIV-1-Infected Individuals.
    Aouri M; Barcelo C; Guidi M; Rotger M; Cavassini M; Hizrel C; Buclin T; Decosterd LA; Csajka C;
    Antimicrob Agents Chemother; 2017 Jan; 61(1):. PubMed ID: 27799217
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rilpivirine use in the Swiss HIV cohort study: a prospective cohort study.
    Sculier D; Gayet-Ageron A; Battegay M; Cavassini M; Fehr J; Hirzel C; Schmid P; Bernasconi E; Calmy A;
    BMC Infect Dis; 2017 Jul; 17(1):476. PubMed ID: 28683720
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pre-existent NRTI and NNRTI resistance impacts on maintenance of virological suppression in HIV-1-infected patients who switch to a tenofovir/emtricitabine/rilpivirine single-tablet regimen.
    Armenia D; Di Carlo D; Calcagno A; Vendemiati G; Forbici F; Bertoli A; Berno G; Carta S; Continenza F; Fedele V; Bellagamba R; Cicalini S; Ammassari A; Libertone R; Zaccarelli M; Ghisetti V; Andreoni M; Ceccherini-Silberstein F; Bonora S; Di Perri G; Antinori A; Perno CF; Santoro MM
    J Antimicrob Chemother; 2017 Mar; 72(3):855-865. PubMed ID: 27999048
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rilpivirine exposure in plasma and sanctuary site compartments after switching from nevirapine-containing combined antiretroviral therapy.
    Mora-Peris B; Watson V; Vera JH; Weston R; Waldman AD; Kaye S; Khoo S; Mackie NE; Back D; Winston A
    J Antimicrob Chemother; 2014 Jun; 69(6):1642-7. PubMed ID: 24521854
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial.
    Molina JM; Cahn P; Grinsztejn B; Lazzarin A; Mills A; Saag M; Supparatpinyo K; Walmsley S; Crauwels H; Rimsky LT; Vanveggel S; Boven K;
    Lancet; 2011 Jul; 378(9787):238-46. PubMed ID: 21763936
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics and pharmacodynamics of the nucleoside sparing dual regimen containing rilpivirine plus darunavir/ritonavir in treatment-naïve HIV-1-infected individuals.
    Jackson A; Else L; Higgs C; Karolia Z; Khoo S; Back D; Devitt E; Pozniak A; Boffito M
    HIV Clin Trials; 2018 Feb; 19(1):31-37. PubMed ID: 29189101
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Switching to a rilpivirine/emtricitabine/tenofovir single-tablet regimen in RNA-suppressed patients infected with human immunodeficiency virus 1: Effectiveness, safety and costs at 96 weeks.
    Arrabal-Durán P; Rodríguez-González CG; Chamorro-de-Vega E; Gijón-Vidaurreta P; Herranz-Alonso A; Sanjurjo-Sáez M
    Int J Clin Pract; 2017 Aug; 71(8):. PubMed ID: 28722790
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma Tenofovir, Emtricitabine, and Rilpivirine and Intracellular Tenofovir Diphosphate and Emtricitabine Triphosphate Pharmacokinetics following Drug Intake Cessation.
    Dickinson L; Yapa HM; Jackson A; Moyle G; Else L; Amara A; Khoo S; Back D; Karolia Z; Higgs C; Boffito M
    Antimicrob Agents Chemother; 2015 Oct; 59(10):6080-6. PubMed ID: 26195515
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Switching from tenofovir/emtricitabine and nevirapine to a tenofovir/emtricitabine/rilpivirine single-tablet regimen in virologically suppressed, HIV-1-infected subjects.
    Allavena C; Dailly E; Reliquet V; Bonnet B; Pineau S; André-Garnier E; Boutoille D; Bouquié R; Raveleau A; Bouchez S; Billaud E; Raffi F
    J Antimicrob Chemother; 2014 Oct; 69(10):2804-8. PubMed ID: 24907142
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Steady-state pharmacokinetics of rilpivirine under different meal conditions in HIV-1-infected Ugandan adults.
    Lamorde M; Walimbwa S; Byakika-Kibwika P; Katwere M; Mukisa L; Sempa JB; Else L; Back DJ; Khoo SH; Merry C
    J Antimicrob Chemother; 2015 May; 70(5):1482-6. PubMed ID: 25652748
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 96-week resistance analyses of the STaR study: rilpivirine/emtricitabine/tenofovir DF versus efavirenz/emtricitabine/tenofovir DF in antiretroviral-naive, HIV-1-infected subjects.
    Porter DP; Kulkarni R; Fralich T; Miller MD; White KL
    HIV Clin Trials; 2015; 16(1):30-8. PubMed ID: 25777187
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of a switch to rilpivirine-based regimens in treatment-experienced HIV-1-infected patients: a cohort study.
    Gazaignes S; Resche-Rigon M; Gatey C; Yang C; Denis B; Fonsart J; Desseaux K; Guionie M; Rozenbaum W; Delaugerre C; Molina JM
    Antivir Ther; 2016; 21(4):329-36. PubMed ID: 26566057
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Usefulness of an HIV DNA resistance genotypic test in patients who are candidates for a switch to the rilpivirine/emtricitabine/tenofovir disoproxil fumarate combination.
    Lambert-Niclot S; Allavena C; Grude M; Flandre P; Sayon S; Andre E; Wirden M; Rodallec A; Jovelin T; Katlama C; Calvez V; Raffi F; Marcelin AG
    J Antimicrob Chemother; 2016 Aug; 71(8):2248-51. PubMed ID: 27231280
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lipid profile changings after switching from rilpivirine/tenofovir disoproxil fumarate/emtricitabine to rilpivirine/tenofovir alafenamide/emtricitabine: Different effects in patients with or without baseline hypercholesterolemia.
    Taramasso L; Di Biagio A; Riccardi N; Briano F; Di Filippo E; Comi L; Mora S; Giacomini M; Gori A; Maggiolo F
    PLoS One; 2019; 14(10):e0223181. PubMed ID: 31603906
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of PCR Signal and Therapeutic Drug Monitoring in a Switch Cohort Study to Tenofovir/Emtricitabine/Rilpivirine: A W96 Follow-Up.
    Charpentier C; Lê MP; Joly V; Visseaux B; Lariven S; Phung B; Yéni P; Yazdanpanah Y; Descamps D; Peytavin G; Landman R
    PLoS One; 2015; 10(7):e0134430. PubMed ID: 26226257
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rilpivirine and cabotegravir trough concentrations in people with HIV on long-term treatment with long-acting injectable antiretrovirals.
    Cossu MV; Cattaneo D; Moschese D; Giacomelli A; Soloperto S; D'Avolio A; Antinori S; Gori A; Rizzardini G; Gervasoni C
    J Antimicrob Chemother; 2024 May; 79(5):1126-1132. PubMed ID: 38530862
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.